| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.006 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.094 | 0.007 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.092 | 0.007 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.007 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.15 | 0.007 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.008 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.008 |